Philochem AG

Philochem is a fully owned daughter company of Philogen and represents the Discovery Unit of the Philogen group. Philochem is based in Otelfingen (Zurich, Switzerland) and was founded in 2006, with the mission to innovate ligand discovery and medicinal target identification. Philochem has discovered innovative methodologies for biotechnology product development: - isolation of human monoclonal antibodies from large combinatorial libraries; - development of armed antibodies (immunocytokines and antibody-drug conjugates); - discovery and validation of vascular markers of pathology using a perfusion-based chemical proteomics approach; - design, construction and screening of DNA-encoded chemical libraries of unprecedented quality and size. These technologies are integrated into drug discovery programs. The most promising candidate products are further developed in the Siena-based Philogen facilities. Here production according to GMP standards and clinical trials are conducted with the aim of developing superior products for the imaging and treatment of serious angiogenesis-related diseases. Philochem has a proven track record in partnering activities, and is currently involved in several projects with leading pharmaceutical companies interested in Philochem’s innovative technology platforms.